Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970409 | 0.98 | GSR (0.44) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL8970155 | 0.98 | GSR (0.44) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL23107037 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL23108731 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL23114343 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL23114340 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL23114342 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL8970109 | 0.95 | GSR (0.38) | GSRCA1CA2CA4NPY1R | |
| SCHEMBL804681 | 0.85 | — | — | |
| SCHEMBL10111314 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4254288-A | OF ALICYCLICS TO AROMATICS; CATALYST OF PALLADIUM, SODIUM CARBONATE, SULFUR | COALITE GROUP LIMITED (GB) | 1981-03-03 | — | — | US | claimed |
| US-4241225-A | FULLER'S EARTH AS CATALYST | COALITE AND CHEMICAL PRODUCTS LIMITED (GB) | 1980-12-23 | — | — | US | claimed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-0376294-B1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI LTD (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5370821-A | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5269965-A | Optically active compounds, liquid crystal compositions comprising said compounds and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0376294-A1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI, LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4254288-A | OF ALICYCLICS TO AROMATICS; CATALYST OF PALLADIUM, SODIUM CARBONATE, SULFUR | COALITE GROUP LIMITED (GB) | 1981-03-03 | — | — | US | disclosed |
| US-4241225-A | FULLER'S EARTH AS CATALYST | COALITE AND CHEMICAL PRODUCTS LIMITED (GB) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | GSR 1970/4885CA1 4389/4885CA2 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.